Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ai Ni

Showing results (91-100 of 108) with videos related to

Pageof 11
Sort By:
Cold Spring Harbor Molecular Case Studies|April 3, 2019
Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with <i>KRAS</i> G12D-mutant lung cancersAlexander Drilon, Adam J Schoenfeld, Kathryn C Arbour, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 30, 2019
Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indicesNatasha Rekhtman, Patrice Desmeules, Anna M Litvak, et al.
JAMA Oncology|November 12, 2015
Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNAKasmintan A Schrader, Donavan T Cheng, Vijai Joseph, et al.
JTO Clinical and Research Reports|January 5, 2022
Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring <i>KRAS</i> MutationsKathryn C Arbour, Eusebio Manchado, Matthew J Bott, et al.
Biorxiv : the Preprint Server for Biology|April 17, 2026
H3 dopaminylation and CaMKII modulate diffuse midline glioma response to CDK9 inhibitionRebecca L Murdaugh, Brittany R Eberl, Rosemary U Richard, et al.
JCO Precision Oncology|June 14, 2019
Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung CancersMichael Offin, Robin Guo, Stephanie L Wu, et al.
Blood|July 3, 2019
CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphomaCraig S Sauter, Brigitte Senechal, Isabelle Rivière, et al.
European Journal of Cancer (Oxford, England : 1990)|January 28, 2019
Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre studyW Victoria Lai, Louisiane Lebas, Tristan A Barnes, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 19, 2018
Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung CancersAlexander Drilon, Jessica J Lin, Thomas Filleron, et al.
The Journal of Clinical Endocrinology and Metabolism|September 27, 2018
Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid CancersLara A Dunn, Eric J Sherman, Shrujal S Baxi, et al.
Pageof 11

Showing results (91-100 of 108) with videos related to

Sort By:
Pageof 11
Cold Spring Harbor Molecular Case Studies|April 3, 2019
Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with <i>KRAS</i> G12D-mutant lung cancersAlexander Drilon, Adam J Schoenfeld, Kathryn C Arbour, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 30, 2019
Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indicesNatasha Rekhtman, Patrice Desmeules, Anna M Litvak, et al.
JAMA Oncology|November 12, 2015
Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNAKasmintan A Schrader, Donavan T Cheng, Vijai Joseph, et al.
JTO Clinical and Research Reports|January 5, 2022
Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring <i>KRAS</i> MutationsKathryn C Arbour, Eusebio Manchado, Matthew J Bott, et al.
Biorxiv : the Preprint Server for Biology|April 17, 2026
H3 dopaminylation and CaMKII modulate diffuse midline glioma response to CDK9 inhibitionRebecca L Murdaugh, Brittany R Eberl, Rosemary U Richard, et al.
JCO Precision Oncology|June 14, 2019
Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung CancersMichael Offin, Robin Guo, Stephanie L Wu, et al.
Blood|July 3, 2019
CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphomaCraig S Sauter, Brigitte Senechal, Isabelle Rivière, et al.
European Journal of Cancer (Oxford, England : 1990)|January 28, 2019
Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre studyW Victoria Lai, Louisiane Lebas, Tristan A Barnes, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 19, 2018
Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung CancersAlexander Drilon, Jessica J Lin, Thomas Filleron, et al.
The Journal of Clinical Endocrinology and Metabolism|September 27, 2018
Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid CancersLara A Dunn, Eric J Sherman, Shrujal S Baxi, et al.
Pageof 11